Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis

References

• MS Trust Types Of MS. 2020 Oct 1. [cited 2022 Feb 8]. Available fromhttps://www.Mstrust.Org.Uk/About-Ms/What-Ms/Types-Ms
   Google Scholar
• MSIF & WHO. 2013. Atlas of Ms 2013: mapping multiple sclerosis around the world. [cited 2014 Sep 1]. Available from: https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
   Google Scholar
• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019b;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Montgomery SM, Kusel J, Nicholas R, et al. Costs and effectiveness of Fingolimod Versus Alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. J Med Econ. 2017;20(9):962–973.
   PubMed Web of Science ®Google Scholar
• Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180–1188.
   PubMed Web of Science ®Google Scholar
• Kurtzke J. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio doctoralis. Neurol Sci. 2000;21(6):383.
   PubMed Web of Science ®Google Scholar
• Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005;252(S5):V3–V9.
   PubMedGoogle Scholar
• Ontaneda D, Fox R. Progressive multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):237–243.
   PubMed Web of Science ®Google Scholar
• Huang W, Chen W, Zhang X. Multiple sclerosis: pathology, diagnosis and treatments. Exp Ther Med. 2017 Jun;13(6):3163–3166.
   PubMed Web of Science ®Google Scholar
• Lublin F, Reingold S, Cohen J, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Thompson A, Banwell B, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the Mcdonald criteria. Lancet Neurol. 2018 Feb;17(2):162–173.
   PubMed Web of Science ®Google Scholar
• Tintore M, Arrambide G, Otero-Romero S, et al. The long-term outcomes Of CIS patients in the Barcelona inception cohort: looking back to recognize aggressive Ms. Mult Scler. 2020 Nov;26(13):1658–1669.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zeposia Epar. [cited 2020 Mar 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
   Google Scholar
• European Medicines Agency. Ponvory: pending Ec Decision. [cited 2021 Mar 25]. Available from https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021
   Google Scholar
• Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World Journal Of Clinical Cases: Wjcc. 2015;3(7):545.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of The American Academy Of Neurology. Neurology. 2018;90(17):777–788.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care. 2013;19(17 Suppl):S343–54.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (Ema) 2017. Assessment report: ocrevus. [cited 2017 Nov 9]. Available from: https://Www.Ema.Europa.Eu/En/Documents/Assessment-Report/Ocrevus-Epar-Public-Assessment-Report_En.Pdf
   Google Scholar
• Costello K, Kalb R, Antel J, et al. 2019. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence: a consensus paper by the multiple sclerosis coalition. Society, S NM, editor. A Consensus Paper By The Multiple Sclerosis Coalition Ed.
   Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. Ectrims/Ean guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.
   PubMed Web of Science ®Google Scholar
• Comi G, Dalla Costa G, Moiola L. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials? Expert Rev Neurother. 2021 Jan;21(1):21–34.
   PubMed Web of Science ®Google Scholar
• Sorensen P, Sellebjerg F, Hartung H, et al. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain. 2020 Sep 1;143(9):2637–2652.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 2013;6(3):161–173.
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. Mabs. 2013;5(1):22–33.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010 May-Jun;2(3):256–265.
   PubMed Web of Science ®Google Scholar
• Cataldi M, Vigliotti C, Mosca T, et al. Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18(6):1249. Pmc5486072.
   PubMed Web of Science ®Google Scholar
• Viola M, Sequeira J, Seica R, et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release. 2018;286:301–314.
   PubMed Web of Science ®Google Scholar
• Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014;42(11):1881–1889.
   PubMedGoogle Scholar
• Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. Ebiomedicine. 2017;16:41–50. Pmc5474520.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous Ofatumumab in patients with relapsing-remitting multiple sclerosis: the mirror study. Neurology. 2018;90(20):E1805–E1814 . Pmc5957306.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research: Ocrelizumab. cited 2016 Apr 28. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053orig1s000medr.pdf
   Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other Cd20(+) B-Cell- depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835–841. Pmc5722762.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al., I. Opera, And O. I. C. Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Ramwadhdoebe T, Van Baarsen L, Boumans M, et al. Effect of rituximab treatment on T And B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1075–1085.
   PubMed Web of Science ®Google Scholar
• Gingele S, Jacobus TL, Konen FF, et al. Ocrelizumab depletes CD20+ T Cells in multiple sclerosis patients. Cells. 2019;8(1):12.
   Web of Science ®Google Scholar
• Ofatumumab Core Data Sheet V1.0. 2020 Jan 23. [cited 2022 Feb 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdf
   Google Scholar
• Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase Ii trial. Neurology. 2010;74(23):1860–1867. 2882224.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-Cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Tesser J, Sewell K. Biosimilars have arrived: rituximab. Arthritis. 2018;2018:3762864. Published 2018 Mar 22.
   PubMedGoogle Scholar
• Kappos L, Li D, Calabresi Pa OP, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 Nov 19;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Babiker H, Glode A, Cooke L, et al. Ublituximab for the treatment of Cd20 Positive B-Cell malignancies. Expert Opin Investig Drugs. 2018 Apr;27(4):407–412.
   PubMed Web of Science ®Google Scholar
• Fox E, Lovett-Racke AE, and Gormley M, et al. A phase 2 multicenter study of ublituximab, A novel glycoengineered anti-Cd20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–429.
   Web of Science ®Google Scholar
• Crofford LJ, Nyhoff LE, Sheehan JH, et al. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016;12(7):763–773.
   PubMed Web of Science ®Google Scholar
• Traynor K. Ofatumumab Approved For Advanced Cll. Am J Health Syst Pharm. 2009 Dec 1;66(23):2062.
   Web of Science ®Google Scholar
• Østergaard M, Baslund B, Rigby W, et al. A human anti-Cd20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, Phase I/Ii study. Arthritis Rheum. 2010 Aug;62(8):2227–2238.
   PubMed Web of Science ®Google Scholar
• Sorensen P, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a Phase 2 study. Neurology. 2014 Feb 18;82(7):573–581.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fox E, Goodyear A, et al. Onset of B-Cell depletion and suppression of mri activity with ofatumumab treatment in relapsing multiple sclerosis: the aplios study (3971). Neurology. 2020;94(15 Supplement):3971.
   Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al., ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546–557.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Seze JD, Cross AH, et al. Serum immunoglobulin levels and infections in relapsing multiple sclerosis. Ecf 28th Annual Meeting, Baveno, Italy. Abstract 33, 2020
   Google Scholar
• Kappos L, Wolinsky J, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. Jama Neurol. 2020;77(9):1132–1140.
   PubMed Web of Science ®Google Scholar
• Winkelmann A, Loebermann M, Reisinger E, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217–233.
   PubMed Web of Science ®Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. Jama Neurol. 2020Feb1;77(2):184–191.
   PubMed Web of Science ®Google Scholar
• Hs N, Rosenbult C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf. 2020 Sep;19(9):1069–1094.
   PubMed Web of Science ®Google Scholar
• Raisch DW, Rafi JA, Chen C, et al. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–1011.
   PubMed Web of Science ®Google Scholar
• Sormani M, De Rossi N, Schiavetti I, et al. Musc-19 Study Group. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021 Apr;89(4):780–789.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). 2016 Feb 29. [cited 2022 Feb 8]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b
   Google Scholar
• Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020 May;87(5):688–699.
   PubMed Web of Science ®Google Scholar
• O’connor P, Comi G, Freedman M, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized temso study [published correction appears in neurology. 2016 Oct 4;87(14):1524]. Neurology. 2016;86(10):920–930.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Haggiag S, and Tortorella C, et al. Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler. 2021;27(9):1391–1402.
   Google Scholar
• Tran V, Miller P, Jarrar R, et al. Real world efficacy and safety profile of ocrelizumab therapy in patients with multiple sclerosis. Ectrims. 2019; Ep1557.
   Google Scholar
• Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013 Feb;33(2):388–396.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, and Paley MA, et al. Effect of immunosuppression on the Immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med. 2021 Nov;174(11):1572–1585 .
   Web of Science ®Google Scholar
• Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020 Nov;202(2):149–161.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Kesimpta: pending Ec decision. cited 2021 Jan 29. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021
   Google Scholar
• Comi G, Bar‐Or A, Lassmann H, et al. Expert panel of the 27th annual meeting of the European charcot foundation. Role of B Cells in multiple sclerosis and related disorders. Annals of Neurology. 2021 Jan;89(1):13–23.
   PubMed Web of Science ®Google Scholar